The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma.

Trial Profile

The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Aug 2015 Planned End Date changed from 1 Apr 2015 to 1 Jan 2020 as reported by ClinicalTrials.gov
    • 19 Aug 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Dec 2019 as reported by ClinicalTrials.gov
    • 10 Dec 2012 Interim results from safety analysis of 100 patients presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top